Adagio Medical is an innovator in catheter-based ablation technologies, centered on its proprietary Ultra-Low Temperature Cryoablation (ULTC) platform. The company’s flagship vCLAS ULTC system creates large, durable lesions that penetrate diseased and healthy cardiac tissue, aiming to raise the safety and efficacy standard for ventricular tachycardia (VT) ablation. To date, more than 350 patients have been treated with Adagio’s technology across regulatory studies, commercial use, and compassionate-use cases. The vCLAS system already holds CE Mark approval and is being evaluated in a U.S. IDE pivotal trial. Adagio is now developing a next-generation ULTC catheter that promises faster performance, smaller size, and greater flexibility. Key near-term objectives include FDA Premarket Approval submission for the vCLAS system via the FULCRUM-VT study, scaling manufacturing, and expanding physician education. The newly raised capital extends the company’s financial runway through these milestones and positions it for eventual global commercialization.

Total raised

$64M

Funding rounds

3

Latest round

Equity

Latest activity

Oct 2025